A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam ...
figshare, 2024
academicJournal
Zugriff:
Background This study aimed to evaluate the efficacy and side effects of first-line afatinib treatment in a real-world setting in Vietnam. Methods This retrospective study was conducted across nine hospitals in Vietnam. Advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) patients who received afatinib as first-line therapy between April 2018 and June 2022 were included, and patient medical records were reviewed. Key outcomes were overall response rate (ORR), time-to-treatment failure (TTF), and tolerability. Results A total of 343 patients on first-line afatinib were eligible for the study. EGFR exon 19 deletion (Del19) alone was detected in 46.9% of patients, L858R mutation alone in 26.3%, and other uncommon EGFR mutations, including compound mutations, in 26.8%. Patients with brain metastases at baseline were 25.4%. Patients who received 40 mg, 30 mg, and 20 mg as starting doses of afatinib were 58.6%, 39.9%, and 1.5%, respectively. The ORR was 78.1% in the ...
Titel: |
A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam ...
|
---|---|
Autor/in / Beteiligte Person: | Pham, Cam Phuong ; Nguyen, Thi Thai Hoa ; Do, Anh Tu ; Nguyen, Tuan Khoi ; Hoang, Thi Anh Thu ; Le, Tuan Anh ; Vuong, Dinh Thy Hao ; Nguyen, Dac Nhan Tam ; Dang, Van Khiem ; Nguyen, Thi Oanh ; Pham, Van Luan ; Nguyen, Minh Hai ; Vo, Thi Huyen Trang ; Do, Hung Kien ; Vu, Ha Thanh ; Nguyen, Thi Thuy Hang ; Pham, Van Thai ; Trinh, Le Huy ; Nguyen, Khac Dung ; Nguyen, Hoang Gia ; Truong, Cong Minh ; Pham, Tran Minh Chau ; Nguyen, Thi Bich Phuong |
Link: |
|
Veröffentlichung: | figshare, 2024 |
Medientyp: | academicJournal |
DOI: | 10.6084/m9.figshare.c.7060965.v1 |
Schlagwort: |
|
Sonstiges: |
|